Source 1primary paper2024MED
Toolkit/chimeric antigen receptor (CAR) T-cells
chimeric antigen receptor (CAR) T-cells
Also known as: CAR T cells, CAR T-cells
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients with B-cell malignancies and multiple myeloma, they continue to have limited efficacy against most solid tumors.
Usefulness & Problems
Why this is useful
CAR T cells are engineered T-cell therapies used to target cancer, and the review focuses on their development for CNS tumours. The abstract states they are already standard-of-care in some relapsed or refractory haematological malignancies.; cell therapy for malignancies; investigational treatment of CNS tumours; CAR T-cells are engineered T cells used for cancer therapy. In this source, they are presented as successful in hematologic malignancies but less effective in most solid tumors.; cellular immunotherapy
Source:
CAR T cells are engineered T-cell therapies used to target cancer, and the review focuses on their development for CNS tumours. The abstract states they are already standard-of-care in some relapsed or refractory haematological malignancies.
Source:
cell therapy for malignancies
Source:
investigational treatment of CNS tumours
Source:
CAR T-cells are engineered T cells used for cancer therapy. In this source, they are presented as successful in hematologic malignancies but less effective in most solid tumors.
Source:
cellular immunotherapy
Problem solved
The approach is being developed to provide new treatment options for CNS tumours, which often have poor prognosis and need new therapies.; provides an adoptive cellular immunotherapy approach for cancers with poor prognosis and limited treatment options; The tool addresses cancer treatment through engineered T-cell targeting. The abstract specifically notes strong clinical success in B-cell malignancies and multiple myeloma.; targeted treatment of B-cell malignancies and multiple myeloma
Source:
The approach is being developed to provide new treatment options for CNS tumours, which often have poor prognosis and need new therapies.
Source:
provides an adoptive cellular immunotherapy approach for cancers with poor prognosis and limited treatment options
Source:
The tool addresses cancer treatment through engineered T-cell targeting. The abstract specifically notes strong clinical success in B-cell malignancies and multiple myeloma.
Source:
targeted treatment of B-cell malignancies and multiple myeloma
Problem links
provides an adoptive cellular immunotherapy approach for cancers with poor prognosis and limited treatment options
LiteratureThe approach is being developed to provide new treatment options for CNS tumours, which often have poor prognosis and need new therapies.
Source:
The approach is being developed to provide new treatment options for CNS tumours, which often have poor prognosis and need new therapies.
targeted treatment of B-cell malignancies and multiple myeloma
LiteratureThe tool addresses cancer treatment through engineered T-cell targeting. The abstract specifically notes strong clinical success in B-cell malignancies and multiple myeloma.
Source:
The tool addresses cancer treatment through engineered T-cell targeting. The abstract specifically notes strong clinical success in B-cell malignancies and multiple myeloma.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
Computational DesignTarget processes
recombinationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
must overcome persistence limitations; must function in immunosuppressive tumour microenvironments; must traffic into tumours; CNS applications must contend with the blood-brain barrier and neurotoxicity risk; This source discusses T-cell engineering and CAR design as prerequisites for generating more potent CAR T-cells. Specific manufacturing details are not provided in the abstract.; performance in pediatric solid tumors is limited by incomplete understanding of tumor microenvironment mechanisms
The abstract states CAR T-cell therapy remains largely ineffective in solid tumours because of limited persistence, immunosuppressive tumour microenvironments, and poor trafficking, with added CNS-specific barriers such as the blood-brain barrier and neurotoxicity concerns.; remains largely ineffective in solid tumours; limited CAR T cell persistence; immunosuppressive tumour microenvironment; limited trafficking of CAR T cells into tumours; blood-brain barrier poses an additional challenge in CNS tumours; concerns over treatment-related neurotoxicities; The abstract states that CAR T-cells continue to have limited efficacy against most solid tumors. It also notes limited mechanistic understanding of pediatric solid-tumor microenvironments.; limited efficacy against most solid tumors
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
mixedHuman Clinicaltherapeutic use
Inferred from claim c5 during normalization. Clinical trials in adult and paediatric patients with primary CNS tumours have provided signals of efficacy for CAR T cells. Derived from claim c5.
Source:
Supporting Sources
Source 2primary paper2026MED
Ranked Claims
Clinical trials in adult and paediatric patients with primary CNS tumours have provided signals of efficacy for CAR T cells.
CAR T cells have become standard-of-care therapies for certain relapsed and/or refractory haematological malignancies.
CNS tumours present additional challenges for CAR T-cell therapy, including the blood-brain barrier and concerns over treatment-related neurotoxicities.
CAR T-cell therapy remains largely ineffective in solid tumours.
Limited CAR T-cell persistence, the immunosuppressive tumour microenvironment, and limited trafficking into tumours contribute to the limited effectiveness of CAR T cells in solid tumours.
Current T-cell engineering has leveraged known tumor-microenvironment principles to create more potent CAR T-cells.
In pediatric solid tumors, limited availability of pre- and post-treatment biopsies constrains understanding of tumor-microenvironment mechanisms that exclude effectors and attract immune-suppressive cells.
CAR T-cells have limited efficacy against most solid tumors despite success in B-cell malignancies and multiple myeloma.
Hijacking the tumor chemokine axis for migratory purposes is among the most promising approaches to enhance CAR T-cells.
Novel CAR gating strategies are among the most promising approaches to enhance CAR T-cells for pediatric solid tumors.
Discovery of new oncofetal antigens and progress in CAR design have expanded the pool of candidate antigens for therapeutic development.
The next step for these modified CAR T-cell approaches is clinical validation of promising preclinical findings.
Approval Evidence
2 sources9 linked approval claimsfirst-pass slug chimeric-antigen-receptor-car-t-cells
Chimeric antigen receptor (CAR) T cells have become standard-of-care therapies for patients with certain relapsed and/or refractory haematological malignancies over the past decade.
Source:
Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients with B-cell malignancies and multiple myeloma, they continue to have limited efficacy against most solid tumors.
Source:
clinical signalsupports
Clinical trials in adult and paediatric patients with primary CNS tumours have provided signals of efficacy for CAR T cells.
Source:
clinical statussupports
CAR T cells have become standard-of-care therapies for certain relapsed and/or refractory haematological malignancies.
Source:
disease context challengesupports
CNS tumours present additional challenges for CAR T-cell therapy, including the blood-brain barrier and concerns over treatment-related neurotoxicities.
Source:
limitationsupports
CAR T-cell therapy remains largely ineffective in solid tumours.
Source:
mechanistic barriersupports
Limited CAR T-cell persistence, the immunosuppressive tumour microenvironment, and limited trafficking into tumours contribute to the limited effectiveness of CAR T cells in solid tumours.
Source:
engineering progresssupports
Current T-cell engineering has leveraged known tumor-microenvironment principles to create more potent CAR T-cells.
Source:
knowledge gapsupports
In pediatric solid tumors, limited availability of pre- and post-treatment biopsies constrains understanding of tumor-microenvironment mechanisms that exclude effectors and attract immune-suppressive cells.
Source:
performance limitationsupports
CAR T-cells have limited efficacy against most solid tumors despite success in B-cell malignancies and multiple myeloma.
Source:
target expansionsupports
Discovery of new oncofetal antigens and progress in CAR design have expanded the pool of candidate antigens for therapeutic development.
Source:
Comparisons
Source-stated alternatives
No specific alternative therapeutic platforms are named in the abstract.; The abstract does not name alternative cell therapy platforms, but it contrasts baseline CAR T-cells with modified versions using gating, cytokine-delivery, and chemokine-axis engineering.
Source:
No specific alternative therapeutic platforms are named in the abstract.
Source:
The abstract does not name alternative cell therapy platforms, but it contrasts baseline CAR T-cells with modified versions using gating, cytokine-delivery, and chemokine-axis engineering.
Source-backed strengths
standard-of-care in certain relapsed and/or refractory haematological malignancies; has shown efficacy signals in clinical trials for primary CNS tumours; great success in B-cell malignancies and multiple myeloma
Source:
standard-of-care in certain relapsed and/or refractory haematological malignancies
Source:
has shown efficacy signals in clinical trials for primary CNS tumours
Source:
great success in B-cell malignancies and multiple myeloma
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract does not name alternative cell therapy platforms, but it contrasts baseline CAR T-cells with modified versions using gating, cytokine-delivery, and chemokine-axis engineering.
Shared frame: source-stated alternative in extracted literature
Strengths here: standard-of-care in certain relapsed and/or refractory haematological malignancies; has shown efficacy signals in clinical trials for primary CNS tumours; great success in B-cell malignancies and multiple myeloma.
Relative tradeoffs: remains largely ineffective in solid tumours; limited CAR T cell persistence; immunosuppressive tumour microenvironment.
Source:
The abstract does not name alternative cell therapy platforms, but it contrasts baseline CAR T-cells with modified versions using gating, cytokine-delivery, and chemokine-axis engineering.
Ranked Citations
- 1.
- 2.